|Dr. Pamela Pierce Palmer M.D., Ph.D.||Co-Founder, Chief Medical Officer and Director||645.61k||N/A||54|
|Ms. Jane Wright-Mitchell||Chief Legal Officer||457.32k||N/A||48|
|Mr. Lawrence G. Hamel||Chief Devel. Officer||457.99k||N/A||65|
|Mr. Anil N. Dasu||Chief Engineering Officer||457.99k||N/A||54|
|Mr. Vincent J. Angotti||CEO & Director||N/A||N/A||49|
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. The companys late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Zalviso is approved in the European Union, Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory; and is under development stage in the United States. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
AcelRx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.